Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platinum-based doublet chemotherapy plus 72h continuous IV endostatin in advanced NSCLC
ChiCTR2100046608Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Jiangnan University
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of endostar in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Affiliated Hospital of Jiangnan University. Primary endpoints: Progression-free survival, Overall response rate and 1 more. Started May 2021; status: recruiting.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100046608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046608.